Mr. Legorreta is the founder and has served as Chief Executive Officer of Royalty Pharma plc (Nasdaq: RPRX), a rapidly growing biopharma company and one of the largest dedicated life sciences investors in the world, since September 1996. Mr. Legorreta has also served as the Chairman of the board of directors of Royalty Pharma plc since April 2020. Mr. Legorreta has over 25 years of experience building and managing Royalty Pharma plc. Additionally, Mr. Legorreta is a co-founder of Pharmakon Advisors, LP, a leading provider of debt capital to the life sciences industry, where he has served as a managing member, since April 2009. Mr. Legorreta has served as a director of Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, since November 2019. Mr. Legorreta has served on the Board of Governors of the New York Academy of Sciences since January 2015, the Board of Trustees of Rockefeller University since March 2017, and the Board of Trustees and Compensation, Research and Innovation and Development Committees of the Hospital for Special Surgery since January 2015. Mr. Legorreta has also served on the boards of Brown University, Pasteur Foundation (French: Institut Pasteur), a French non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, Open Medical Institute, an international initiative for medical professionals, which through education and research, aims to improve healthcare on a global scale, and The Park Avenue Armory, a nonprofit cultural institution within the historic Seventh Regiment Armory. Mr. Legorreta is the founder and Chairman of Alianza Médica para la Salud, a non-profit organization dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities. Since its foundation in December 2010, AMSA has provided over 500 scholarships to Mexican and Latin American doctors and healthcare providers to study abroad. Mr. Legorreta is also a founding member of Mount Sinai’s new Institute for Health Equity Research, which is created in May 2020 in part as a response to the health inequities made apparent by COVID-19. Mr. Legorreta received his B.A. degree in Industrial Engineering from Universidad Iberoamericana in Mexico City.
What is Pablo G. Legorreta's net worth?
The estimated net worth of Pablo G. Legorreta is at least $58.13 million as of June 13th, 2024. Legorreta owns 22,617,909 shares of ProKidney stock worth more than $58,128,026 as of December 5th. This net worth estimate does not reflect any other assets that Legorreta may own. Learn More about Pablo G. Legorreta's net worth.
How do I contact Pablo G. Legorreta?
Has Pablo G. Legorreta been buying or selling shares of ProKidney?
Pablo G. Legorreta has not been actively trading shares of ProKidney during the last quarter. Most recently, on Thursday, June 13th, Pablo G. Legorreta bought 22,617,909 shares of ProKidney stock. The stock was acquired at an average cost of $2.42 per share, with a total value of $54,735,339.78. Following the completion of the transaction, the director now directly owns 22,617,909 shares of the company's stock, valued at $54,735,339.78. Learn More on Pablo G. Legorreta's trading history.
Who are ProKidney's active insiders?
Are insiders buying or selling shares of ProKidney?
In the last year, ProKidney insiders bought shares 4 times. They purchased a total of 1,787,716 shares worth more than $1,175,418.66. In the last year, insiders at the sold shares 3 times. They sold a total of 860,642 shares worth more than $2,196,242.64. The most recent insider tranaction occured on November, 13th when Director Brian Jg Pereira sold 502,136 shares worth more than $1,190,062.32. Insiders at ProKidney own 41.5% of the company.
Learn More about insider trades at ProKidney. Information on this page was last updated on 11/13/2025.
